Management of Patients with Relapsed/Refractory Multiple Myeloma: Elsevier CME Independent Conference Highlights from EBMT and EHA 2018
Format: Conference Reporter
Credits: 1.0 AMA PRA Category 1 Credit™
*This webcast is not endorsed by the conference organizer. The Elsevier Office of Continuing Medical Education is an independent medical education company that provides clinical updates, analysis, and expert perspectives through conference-coverage educational programs.
In this CME-accredited webcast, three experts discuss the clinical implications of some of the latest important research on relapsed/refractory multiple myeloma (RRMM). The roundtable discussion covers new data presented at the 2018 annual meetings of the European Hematology Association (EHA) and the European Society for Blood and Marrow Transplantation (EBMT). The topics discussed include: unmet needs in the treatment of RRMM; new data on treatment strategies (including the roles of proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies); and emerging treatments, such as chimeric antigen receptor (CAR) T-cell therapies.